


Taiwan's BioGate Precision Medicine Corp develops pancreatic cancer therapy

07 March 2024 | News

A major global milestone in pancreatic cancer treatment



Taiwan-based BioGate Precision Medicine Corp., a member of Powerchip Group, has unveiled an innovative breakthrough in pancreatic cancer drug development. Dr Frank Huang, Chairman and CEO of BioGate, revealed that BioGate through inhouse R&D has created a targeted therapy biologic, BGX. This was achieved by developing multi-platform technology combining biochemistry, immunology, and molecular biology.

Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates. This achievement represents a major global milestone in pancreatic cancer treatment. BioGate also announced its plan to apply for Taiwan FDA Phase I clinical trials and to seek approval from the US FDA, offering hope and improved care for pancreatic cancer patients in Taiwan region as well as worldwide.

Pancreatic cancer affects 500,000 people globally each year, with over 3,000 cases in Taiwan annually. It is difficult to diagnose early due to its inconspicuous initial symptoms, so most patients are diagnosed at advanced stages.

Current treatments primarily involve chemotherapy combinations, such as Paclitaxel and Gemcitabine. However, these treatments have significant side effects.

Looking forward, Dr Huang revealed that BioGate's groundbreaking targeted therapy biologic agent BGX not only advances pancreatic cancer research, but also holds promise for treating other type of cancers such as lung, colorectal, esophageal, gallbladder, stomach, breast, and prostate cancers. Additionally, BioGate actively seeks strategic partnerships across industry, academia, and research sectors, collaborating with international pharmaceutical companies to jointly develop new drugs and conduct clinical trials.